ReviewMolecular diversity2026
Design strategies, structural insights, and biological potential of amyloid-beta inhibitors in Alzheimer's disease.
Review in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is an insidious neurodegenerative condition characterized by dementia, cognitive decline, and eventual mortality. The pathogenesis of AD is complex, influenced by multiple factors including neurotransmitter deficiencies, particularly acetylcholine (ACh) and the dysregulation of mental homeostasis, reactive oxygen species (ROS), and amyloid-beta (Aβ) peptide accumulation. The latter is firmly linked to the formation of neurofibrillary tangles (NFTs) and amyloid plaques in the cortical and hippocampal regions, which are hallmarks of the disease pathology. Recent advancements in therapeutic strategies have focused on inhibiting the amyloid-beta peptide, a key contributor to AD progression. This study explores the development of novel amyloid-beta inhibitors and their biological activities, focusing on the synthesis of radiolabeled compounds used in the diagnosis and treatment of Alzheimer's disease. Additionally, we explore the roles of crucial enzymes such as Electrophorus electricus acetylcholinesterase (eeAChE), human acetylcholinesterase (hAChE), and human butyrylcholinesterase (hBuChE) in the disease's neurochemical landscape. The goal of this review is to furnish the scientific community with insight into the design of innovative amyloid imaging agents. These agents are based on diverse scaffolds including flavone, pyrimidine, benzimidazole, imidazole, pyridine, pyrrole, quinoline, indanone, acridine, and peptide-based derivatives, serving as core structures for further research and development. This comprehensive evaluation not only elucidates the molecular underpinnings of AD but also propels forward the quest for efficacious diagnostic and therapeutic tools.
Indexed as
Identifiers
40608230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.